HPCAL1 and hepatocellular carcinoma: Paradoxically, tumors deficient for Hpcal1 elicits hypersensitivity to mTORi AZD-8055, indicating that genetic inactivation of Hpcal1 in hepatocytes results in lipid metabolic changes that are critical for HCC progression and also a metabolic vulnerability that offer therapeutic opportunity to mTORi.